[Immuno-, radio-, and chemotherapeutic studies in head and neck cancer : Highlights of the ASCO Annual Meeting 2017]. / Immun-, radio- und chemotherapeutische Studien bei Kopf-Hals-Tumoren : Highlights der ASCO-Jahrestagung 2017.
HNO
; 66(3): 212-218, 2018 Mar.
Article
in De
| MEDLINE
| ID: mdl-29460015
ABSTRACT
In recent years, immunotherapy has been shown to be a promising approach for the treatment of various tumor entities. Due to further pharmacological developments and new studies, the checkpoint inhibitors have now arrived in the clinic. To date, patients with cancers in the head and neck region have benefited from these agents as part of a palliative therapy. Current clinical trials are testing other indications for the checkpoint inhibitors as monotherapy or in combination with other therapeutic approaches. The following article summarizes the highlights of the American Society of Clinical Oncology (ASCO) Annual Meeting.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Head and Neck Neoplasms
Limits:
Humans
Language:
De
Journal:
HNO
Year:
2018
Document type:
Article